GlassScriptPhysician profile
Scott A Rens
NPI 1245390764
$1,050.84
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $431 · 2020: $150 · 2021: $268 · 2022: $158 · 2023: $12.92 · 2024: $30.06.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $42.98.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $42.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $214.84 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $187.12 | 2019 | |
| Janssen Pharmaceuticals, INC | $100.35 | 2019-2024 | Spravato |
| Astrazeneca Pharmaceuticals LP | $77.17 | 2020-2022 | |
| Novo Nordisk INC | $66.09 | 2019-2021 | |
| Abbvie INC. | $61.07 | 2021-2022 | |
| Pfizer INC. | $53.48 | 2019-2023 | |
| Amgen INC. | $43.41 | 2020-2021 | |
| Astellas Pharma US INC | $32.38 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.68 | 2019-2021 | |
| Jazz Pharmaceuticals INC. | $29.66 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $28.63 | 2021 | |
| Lilly USA, LLC | $25.11 | 2021-2024 | Mounjaro |
| Ortho-Clinical Diagnostics, INC. | $24.19 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $23.79 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $15.25 | 2019 | |
| Genentech USA, INC. | $14.91 | 2021 | |
| Merck Sharp & Dohme LLC | $11.92 | 2019 | |
| Sunovion Pharmaceuticals INC. | $9.79 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Rens listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.